Phaseline

Companies › Sun Pharmaceutical Industries

Sun Pharmaceutical Industries: clinical trials, targets and expected readouts

8 active drug programs in 13 registered trials: 5 Phase 3, 5 Phase 2, 2 Phase 1, 1 Phase 4; Immunology, Oncology, Metabolic and endocrine; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Clascoterone
Androgen Receptor antagonist
ARPhase 4Acne Vulgaris–
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA
Aminolevulinic acid prodrug for photodynamic therapy; converted to protoporphyrin IX for p
PPOXPhase 3Actinic KeratosisJan 2027
Tildrakizumab
Interleukin-23 inhibitor
IL12B, IL23APhase 3Active Psoriatic Arthritis; Moderate to Severe Genital Psoriasis; Psoriatic Arthritis; Moderate-to-severe Chronic Plaque PsoriasisFeb 2027
Deuruxolitinib Phosphate (CTP-543)
Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor
JAK1, JAK2, JAK3, TYK2Phase 3Alopecia AreataMay 2027
GL0034
GLP-1 receptor agonist
GLP1RPhase 2Type II Diabetes MellitusApr 2027
Abiraterone acetate
Cytochrome P450 17A1 inhibitor
CYP17A1Phase 2Metastatic CancerDec 2027
Enzalutamide
Androgen Receptor antagonist
ARPhase 2Metastatic CancerDec 2027
Levulan Kerastick (reformulated)
5-aminolevulinic acid (ALA) prodrug for photodynamic therapy
PPOXPhase 1Actinic Keratosis (AK)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04314531TildrakizumabPhase 3Active Psoriatic ArthritisImmunologyJun 2025
NCT06425900ClascoteronePhase 4Acne VulgarisImmunologyMar 2026
NCT07385547GL0034Phase 1Type II Diabetes MellitusMetabolic and endocrineSep 2026
NCT07729579Levulan Kerastick (reformulated)Phase 1Actinic Keratosis (AK)ImmunologyDec 2026
NCT07144852Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALAPhase 3Actinic KeratosisOncologyJan 2027
NCT06611163TildrakizumabPhase 3Moderate to Severe Genital PsoriasisImmunologyFeb 2027
NCT07282743GL0034Phase 2Type II Diabetes MellitusMetabolic and endocrineApr 2027
NCT03898479Deuruxolitinib Phosphate (CTP-543)Phase 2Alopecia AreataImmunologyMay 2027
NCT05422911Abiraterone acetatePhase 2Metastatic CancerOncologyDec 2027
NCT05422911EnzalutamidePhase 2Metastatic CancerOncologyDec 2027
NCT07133308Deuruxolitinib Phosphate (CTP-543)Phase 3Alopecia AreataImmunologyMay 2028
NCT04991116TildrakizumabPhase 3Psoriatic ArthritisImmunologyDec 2028
NCT03997786TildrakizumabPhase 2Moderate-to-severe Chronic Plaque PsoriasisImmunologyAug 2031

From the company's SEC filings

Complete response letters from FDA

Targets

PPOX (2) AR (2) JAK1 (1) JAK2 (1) JAK3 (1) TYK2 (1) GLP1R (1) IL12B (1) IL23A (1) CYP17A1 (1)

Companies with the same targets

AbbVie Pfizer Incyte Alfasigma Takeda LEO Pharma Eisai Suzhou Zelgen Biopharmaceuticals Johnson & Johnson (Janssen) Novartis

Companies built like this

Chong Kun Dang Pharmaceutical Sunshine Guojian Pharmaceutical (Shanghai) Ganzhou Hemay Pharmaceutical Antengene Biologics Molecure

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.